Denali Therapeutics Reaches Analyst Target Price
May 28, 2020 at 09:13 AM EDT
In recent trading, shares of Denali Therapeutics Inc (DNLI) have crossed above the average analyst 12-month target price of $26.80, changing hands for $27.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..